PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer - Liu, Bo; Li, Likun; Yang, Guang; Geng, Chuandong; Luo, Yong; Wu, Wenhui; Manyam, Ganiraju C.; Korentzelos, Dimitrios; Park, Sanghee; Tang, Zhe; Wu, Cheng; Dong, Zhenyang; et al. (Clinical cancer research, 2019)
Keywords: Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Cell Line, Tumor; Cyclin-Dependent Kinase 5 - genetics; Cyclin-Dependent Kinase 5 - metabolism; E2F1 Transcription Factor - genetics; E2F1 Transcription Factor - metabolism; Gene Expression Regulation, Neoplastic - drug effects; Humans; Male; Mice, Nude; N-Myc Proto-Oncogene Protein - genetics; N-Myc Proto-Oncogene Protein - metabolism; Neuroendocrine Tumors - drug therapy; Neuroendocrine Tumors - genetics; Neuroendocrine Tumors - metabolism; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Phthalazines - administration & dosage; Piperazines - administration & dosage; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - metabolism; Proteins - genetics; Proteins - metabolism; Pyridinium Compounds - administration & dosage; Receptors, Glucocorticoid - genetics; Receptors, Glucocorticoid - metabolism; Retinoblastoma Binding Proteins - genetics; Retinoblastoma Binding Proteins - metabolism; Signal Transduction - drug effects; Signal Transduction - genetics; Treatment Outcome; Ubiquitin-Protein Ligases - genetics; Ubiquitin-Protein Ligases - metabolism; Xenograft Model Antitumor Assays - methods